Description
JAK2 inhibitor pacritinib significantly benefits patient reported outcomes in myelofibrosis
Article: JAK2 inhibitor pacritinib significantly benefits patient reported outcomes in myelofibrosis
€3.03
Related products
-
Article: Clinically meaningful survival benefit with atezolizumab + nab-paclitaxel in previously untreated patients with PD-L1+ metastatic triple negative breast cancer
€3.03 Add to cart -
Article: Highlights in breast cancer
€3.03 Add to cart -
Article: Highlights in urologic cancer
€3.03 Add to cart -
Article: Highlights in gynaecological cancers
€3.03 Add to cart
